KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Operating Leases (2020 - 2025)

Aquestive Therapeutics (AQST) has 6 years of Operating Leases data on record, last reported at $4.8 million in Q1 2025.

  • For Q1 2025, Operating Leases fell 8.74% year-over-year to $4.8 million; the TTM value through Mar 2025 reached $4.8 million, down 8.74%, while the annual FY2024 figure was $5.0 million, 7.98% down from the prior year.
  • Operating Leases reached $4.8 million in Q1 2025 per AQST's latest filing, down from $5.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.4 million in Q4 2023 and bottomed at $1.5 million in Q2 2022.
  • Average Operating Leases over 5 years is $4.0 million, with a median of $4.9 million recorded in 2024.
  • The widest YoY moves for Operating Leases: up 161.31% in 2022, down 37.81% in 2022.
  • A 5-year view of Operating Leases shows it stood at $1.9 million in 2021, then surged by 161.31% to $5.1 million in 2022, then rose by 6.18% to $5.4 million in 2023, then fell by 7.98% to $5.0 million in 2024, then decreased by 2.94% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $4.8 million in Q1 2025, $5.0 million in Q4 2024, and $5.2 million in Q2 2024.